Glucagon/GLP-1 combined action
Also known as: MEDI0382 · GLP-1/glucagon
The essentials at a glance
Has been studied clinically for glucose control, body weight, and liver and kidney markers.
Distinction: Cotadutide has also been studied for liver and kidney markers, unlike GLP-1 agonists focused purely on glucose and weight.
Prohibited or covered under WADA rules in competitive sport.
The substance is currently being studied in structured human clinical trials, but a general approval does not yet exist.
In clinical research: A clinical-development candidate, not an approved medicinal product.
Research questions
Researchers test whether combining glucagon and GLP-1 signalling increases energy expenditure in addition to appetite suppression. Liver fat levels and weight trajectory are compared against pure GLP-1 agents.
Researchers track changes in body weight, body composition, and metabolic markers such as blood sugar or cholesterol over the course of a study. This is similar to following someone's weight and lab values over months to see broader trends rather than day-to-day fluctuations.
This looks at effects on liver fat, heart function, and kidney markers, organs that are closely linked through shared metabolic and blood flow pathways. Studies typically measure liver fat imaging, blood pressure, and kidney function tests over time.
Simple example
Think of it like a component still being tested in a development workshop, not yet cleared for general use.
Research status means efficacy, dosing, and safety in humans are not yet conclusively established.
Community themes
Personal experience reports and vendor marketing from communities are not scientific proof of efficacy.
In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.
Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.
Users exchange self-assembled combinations of several peptides and compare perceived effects, often without the specific combination ever having been studied. Such stack recommendations are personal opinions, not vetted protocols.
Why individual profiles do not contain mixing instructions
Reconstitution depends on the exact product, label, identity, concentration, sterility and stability. Arithmetic examples appear only in the separately labelled community area and are not recommendations.
Reconstitution & quantitiesOpen basics, units and sourcesUse & mixingEvidence boundary
Clinical studies exist, but general approval does not.
No peptide sales or individual recommendations. A separately labelled community area documents third-party protocol claims without medically endorsing them.
Primary sources
Regulators, trial registries and scientific databases support the classification and carry more weight than vendor or community claims.
